Impax Agrees to Settle Flomax Patent Dispute

Law360, New York (October 7, 2009, 4:59 PM EDT) -- Impax Laboratories Inc. has reached an agreement with drugmakers Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals Inc. to settle a patent dispute related to a generic version of Flomax, a drug used to treat the symptoms of an enlarged prostate.

Impax announced the settlement Wednesday, saying that the agreement will give Impax the opportunity to launch a generic version of Flomax on March 2, 2010, before the expiration of pediatric exclusivity. Additional terms of the settlement were confidential, Impax said.

A spokeswoman for Boehringer Ingelheim confirmed...
To view the full article, register now.